Literature DB >> 24658338

BRCA1 exon 11 a model of long exon splicing regulation.

Michela Raponi1, Lindsay D Smith1, Marco Silipo1, Cristiana Stuani2, Emanuele Buratti2, Diana Baralle1.   

Abstract

BRCA1 exon 11 is one of the biggest human exons, spanning 3426 bases. This gene is potentially involved in DNA repair as well as cell growth and cell cycle control. Exon 11 is regulated at the splicing level producing three main different combinations of BRCA1 mature transcripts; one including the whole of exon 11 (full isoform), one skipping the entire exon (D11 isoform), and one including only 117 base pairs of exon 11 (D11q isoform). Using minigene and deletion analyses, we have previously described important splicing regulatory sequences located at the beginning of this exon (5' end). We have now found additional important sequences located at its 3' end. In particular, we describe the presence of a strong splicing enhancer adjacent to the downstream 5' splice site, which minimizes competition from an upstream 5' splice site and so ensures long exon inclusion. Analyses of the proteins binding these RNA sequences have revealed that Tra2beta and hnRNP L are involved in the regulation of BRCA1 exon 11 by influencing the recognition of donor sites. Interestingly, BRCA1 exon 11 carrying deletion of the regulatory sequences bound by these factors also showed unexpected responses to up- or downregulation of these regulatory proteins, suggesting that they can also bind elsewhere in this large exon and elicit different effects on its recognition.   The identification of sequences and proteins relevant for the regulation of BRCA1 exon 11 now provides better knowledge on how this exon is recognized and may represent an important step toward understanding how large exons are regulated.

Entities:  

Keywords:  BRCA; BRCA1; Splicing; Tra2beta; alternative splicing; donor site; exon11; hnRNPL; tra2B

Mesh:

Substances:

Year:  2014        PMID: 24658338      PMCID: PMC4075520          DOI: 10.4161/rna.28458

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  29 in total

1.  Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing.

Authors:  Sharan Paul; Warunee Dansithong; Dongho Kim; John Rossi; Nicholas J G Webster; Lucio Comai; Sita Reddy
Journal:  EMBO J       Date:  2006-08-31       Impact factor: 11.598

Review 2.  Regulation of alternative splicing: more than just the ABCs.

Authors:  Amy E House; Kristen W Lynch
Journal:  J Biol Chem       Date:  2007-11-16       Impact factor: 5.157

Review 3.  Chromatin and epigenetic regulation of pre-mRNA processing.

Authors:  Seth J Brown; Peter Stoilov; Yi Xing
Journal:  Hum Mol Genet       Date:  2012-08-29       Impact factor: 6.150

4.  Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.

Authors:  T I Orban; E Olah
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

5.  Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.

Authors:  D A Favy; S Lafarge; P Rio; C Vissac; Y J Bignon; D Bernard-Gallon
Journal:  Biochem Biophys Res Commun       Date:  2000-07-21       Impact factor: 3.575

6.  A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.

Authors:  David J Sanz; Alberto Acedo; Mar Infante; Mercedes Durán; Lucía Pérez-Cabornero; Eva Esteban-Cardeñosa; Enrique Lastra; Franco Pagani; Cristina Miner; Eladio A Velasco
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.

Authors:  Michela Raponi; Jana Kralovicova; Ellen Copson; Petr Divina; Diana Eccles; Peter Johnson; Diana Baralle; Igor Vorechovsky
Journal:  Hum Mutat       Date:  2011-03-08       Impact factor: 4.878

Review 8.  Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.

Authors:  Naoko Okumura; Hitomi Yoshida; Yasuko Kitagishi; Yuri Nishimura; Satoru Matsuda
Journal:  Biochem Biophys Res Commun       Date:  2011-08-27       Impact factor: 3.575

9.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.

Authors:  Gene Yeo; Christopher B Burge
Journal:  J Comput Biol       Date:  2004       Impact factor: 1.479

10.  Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1.

Authors:  Michela Raponi; Emanuele Buratti; Miriam Llorian; Cristiana Stuani; Christopher W J Smith; Diana Baralle
Journal:  FEBS J       Date:  2008-11-01       Impact factor: 5.542

View more
  9 in total

1.  Transformer 2β homolog (Drosophila) (TRA2B) regulates protein kinase C δI (PKCδI) splice variant expression during 3T3L1 preadipocyte cell cycle.

Authors:  Rekha S Patel; Gay Carter; Denise R Cooper; Hercules Apostolatos; Niketa A Patel
Journal:  J Biol Chem       Date:  2014-09-26       Impact factor: 5.157

Review 2.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

3.  Bioinformatics detection of modulators controlling splicing factor-dependent intron retention in the human brain.

Authors:  Steven X Chen; Ed Simpson; Jill L Reiter; Yunlong Liu
Journal:  Hum Mutat       Date:  2022-05-10       Impact factor: 4.700

4.  Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.

Authors:  Desislava Dimitrova; Ilary Ruscito; Sven Olek; Rolf Richter; Alexander Hellwag; Ivana Türbachova; Hannah Woopen; Udo Baron; Elena Ioana Braicu; Jalid Sehouli
Journal:  Tumour Biol       Date:  2016-06-14

5.  Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing.

Authors:  Jessica S Elman; Thomas K Ni; Kristen E Mengwasser; Dexter Jin; Ania Wronski; Stephen J Elledge; Charlotte Kuperwasser
Journal:  Cell Rep       Date:  2019-09-24       Impact factor: 9.423

Review 6.  Splicing dysregulation as a driver of breast cancer.

Authors:  Abigail Read; Rachael Natrajan
Journal:  Endocr Relat Cancer       Date:  2018-05-30       Impact factor: 5.678

Review 7.  Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Authors:  Tao Xie; Kristie-Ann Dickson; Christine Yee; Yue Ma; Caroline E Ford; Nikola A Bowden; Deborah J Marsh
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

8.  The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Authors:  Yifan Wang; Andrea J Bernhardy; Cristina Cruz; John J Krais; Joseph Nacson; Emmanuelle Nicolas; Suraj Peri; Hanneke van der Gulden; Ingrid van der Heijden; Shane W O'Brien; Yong Zhang; Maribel I Harrell; Shawn F Johnson; Francisco J Candido Dos Reis; Paul D P Pharoah; Beth Karlan; Charlie Gourley; Diether Lambrechts; Georgia Chenevix-Trench; Håkan Olsson; Javier J Benitez; Mark H Greene; Martin Gore; Robert Nussbaum; Siegal Sadetzki; Simon A Gayther; Susanne K Kjaer; Alan D D'Andrea; Geoffrey I Shapiro; David L Wiest; Denise C Connolly; Mary B Daly; Elizabeth M Swisher; Peter Bouwman; Jos Jonkers; Judith Balmaña; Violeta Serra; Neil Johnson
Journal:  Cancer Res       Date:  2016-05-01       Impact factor: 12.701

Review 9.  Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Authors:  Haitao Yang; MariaLynn Jaeger; Averi Walker; Daniel Wei; Katie Leiker; Tao Weitao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.